Jamal et al described the MgGill-Brisbane Symptom Score (MBSS) for evaluating a patient with pancreatic adenocarcinoma. The authors are from McGill University and the University of Queensland in Brisbane.
Parameters:
(1) weight loss
(2) pain
(3) smoker
(4) jaundice
Parameters |
Finding |
Points |
---|---|---|
weight loss |
none or <= 10% |
0 |
|
> 10% |
8 |
pain |
absent |
0 |
|
present |
5 |
smoker |
no |
0 |
|
yes |
4 |
jaundice |
absent |
0 |
|
present |
4 |
total score =
= SUM(points for all 4 parameters)
Interpreation:
• minimum score: 0
• maximum score: 21
• The higher the score the worse the prognosis.
Score |
Group |
Survival at 1 Year (Original Cohort with Unresectable Disease) |
---|---|---|
0 to 9 |
low |
62% |
12 to 21 |
high |
10% |
Score |
Group |
Median Survival (Patients Undergoing Surgery) |
---|---|---|
0 to 9 |
low |
45 months |
12 to 21 |
high |
17 months |
Purpose: To evaluate a patient with pancreatic adenocarcinoma using the McGill-Brisbane Symptom Score (MBSS).
Specialty: Hematology Oncology, Surgery, general, Gastroenterology
Objective: severity, prognosis, stage
ICD-10: C25,